1

1	Six-month sequelae of post-vaccination SARS-CoV-2			
2	infection: a retrospective cohort study of 10,024			
3 4	breakthrough infections			
5	Maxime Taquet, PhD, ^{1,2} Quentin Dercon, MSc, ^{1,3} Paul J Harrison, FRCPsych ^{1,2}			
6				
7	¹ Department of Psychiatry, University of Oxford, Oxford, U.K.			
8	² Oxford Health NHS Foundation Trust, Oxford, U.K.			
9	³ MRC Cognition & Brain Sciences Unit, University of Cambridge, U.K.			
10				
11	Correspondence: Maxime Taquet, Department of Psychiatry, University of Oxford,			
12	Warneford Hospital, Oxford OX3 7JX, United Kingdom, maxime.taquet@medsci.ox.ac.uk			
13				
14				
15	3492 words 1 Table 3 Figures 28 References Appendix			

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

16 Abstract

17 Vaccination has proven effective against infection with SARS-CoV-2, as well as death and hospitalisation following COVID-19 illness. However, little is known about the effect of 18 19 vaccination on other acute and post-acute outcomes of COVID-19. Data were obtained from 20 the TriNetX electronic health records network (over 81 million patients mostly in the USA). 21 Using a retrospective cohort study and time-to-event analysis, we compared the incidences of 22 COVID-19 outcomes between individuals who received a COVID-19 vaccine (approved for 23 use in the USA) at least 2 weeks before SARS-CoV-2 infection and propensity score-24 matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine. 25 Outcomes were ICD-10 codes representing documented COVID-19 sequelae in the 6 months 26 after a confirmed SARS-CoV-2 infection (recorded between January 1 and August 31, 2021). 27 Associations with the number of vaccine doses (1 vs. 2) and age (< 60 vs. > 60 years-old) were assessed. Among 10,024 vaccinated individuals with SARS-CoV-2 infection, 9479 28 29 were matched to unvaccinated controls. Receiving at least one COVID-19 vaccine dose was 30 associated with a significantly lower risk of respiratory failure, ICU admission, 31 intubation/ventilation, hypoxaemia, oxygen requirement, hypercoagulopathy/venous 32 thromboembolism, seizures, psychotic disorder, and hair loss (each as composite endpoints 33 with death to account for competing risks; HR 0.70-0.83, Bonferroni-corrected p<.05), but 34 not other outcomes, including long-COVID features, renal disease, mood, anxiety, and sleep 35 disorders. Receiving 2 vaccine doses was associated with lower risks for most outcomes. 36 Associations between prior vaccination and outcomes of SARS-CoV-2 infection were 37 marked in those < 60 years-old, whereas no robust associations were observed in those ≥ 60 38 years-old. In summary, COVID-19 vaccination is associated with lower risk of several, but 39 not all, COVID-19 sequelae in those with breakthrough SARS-CoV-2 infection. These benefits of vaccination were clear in younger people but not in the over-60s. The findings 40

- 3
- 41 may inform service planning, contribute to forecasting public health impacts of vaccination
- 42 programmes, and highlight the need to identify additional interventions for COVID-19
- 43 sequelae.

4

44 Introduction

The observation that individuals can be infected with SARS-CoV-2 after being vaccinated 45 46 against COVID-19 (so-called breakthrough infections) has caused concerns (Nixon and 47 Ndhlovu, 2021). These concerns are mitigated by abundant evidence that the risk of severe 48 COVID-19 illness (as proxied by hospitalisation, admission to intensive care unit, and 49 mortality) is lessened by vaccination (Agrawal et al., 2021; Antonelli et al., 2021; Bahl et al., 50 2021; Butt et al., 2021; Cabezas et al., 2021; Glatman-Freedman et al., 2021; Haas et al., 51 2021; Hyams et al., 2021; Mateo-Urdiales et al., 2021; Roest et al., 2021). One case-control 52 study investigated the association between self-reported SARS-CoV-2 infection in 908 pairs 53 of vaccinated and unvaccinated individuals and self-reported symptoms beyond 28 days 54 (Antonelli et al., 2021). It found that compared to unvaccinated individuals, those with 55 breakthrough infection were at a lower risk of symptoms beyond 28 days. 56 However, how COVID-19 vaccination affects the broad spectrum of sequelae of SARS-CoV-57 58 2 infection remains elusive. In particular, it is unknown if vaccinated individuals are at the 59 same risk as unvaccinated individuals of venous thromboembolisms, ischaemic strokes, 60 neuropsychiatric complications, long-COVID presentations, and other post-acute sequelae 61 following infection with SARS-CoV-2. In addition, unvaccinated people might have health 62 behaviours related to vaccination hesitancy (Latkin et al., 2021), and this potential source of 63 bias has not been addressed by previous studies.

64

65 This cohort study based on electronic health records compares the 6-months outcomes of 66 SARS-CoV-2 infection among individuals who were (vs. those who were not) vaccinated 67 against COVID-19. We investigated a range of outcomes (both acute and post-acute) with 68 documented associations with COVID-19 across multiple body systems.

69 Methods

5

70 Data and study design

71 The study used TriNetX Analytics, a federated network of linked EHRs recording

anonymized data from 59 healthcare organizations (HCOs), primarily in the USA, totalling

73 81 million patients. Available data include demographics, diagnoses (ICD-10 codes),

74 procedures (Current Procedural Terminology [CPT] codes), and measurements (e.g. blood

75 pressure). The HCOs consist in a mixture of primary care centres, hospitals, and specialist

vnits. They provide data from uninsured as well as insured individuals. Data de-identification

is attested to and receives a formal determination by a qualified expert as defined in Section

78 §164.514(b)(1) of the HIPAA Privacy Rule. This formal determination supersedes TriNetX's

79 waiver from the Western Institutional Review Board (IRB). Using the TriNetX user interface,

80 cohorts are created based on inclusion and exclusion criteria, matched for confounding

81 variables, and compared for outcomes of interest over specified time periods. For further

82 details about TriNetX, see Appendix pp. 1-2.

83

84 Cohorts

85 Both the primary and control cohorts were defined as all patients who had, between January

86 1, 2021 and August 31, 2021, a confirmed SARS-CoV-2 infection, which we defined as

87 either a confirmed diagnosis of COVID-19 (ICD-10 code U07.1) or a first positive PCR test

for SARS-CoV-2. In the primary cohort, patients were included only if their confirmed

89 SARS-CoV-2 infection occurred at least 14 days after a recorded administration of a COVID-

90 19 vaccine approved for use in the USA (i.e. BNT162b2 'Pfizer/BioNTech', mRNA-1273

91 'Moderna', or Ad26.COV2.S 'Janssen'). In the control cohort, patients were included only if

92 no recorded vaccine against COVID-19 was recorded before their SARS-CoV-2 infection

93 and if they had received a vaccine against influenza at any time. In the USA, the Centers for

6

Disease Control and Prevention (CDC) recommend yearly influenza vaccination to everyone
over the age of 6 months. This inclusion criterion thus excludes patients with obvious vaccine
hesitancy (so-called 'anti-vaxxers') as this is correlated with other health-related behaviours
that might confound associations with COVID-19 outcomes (Latkin et al., 2021). More
details are provided in the Appendix pp. 2-4.

99

100 Covariates

A set of established and suspected risk factors for COVID-19 and for more severe COVID-19 101 102 illness was used (de Lusignan et al., 2020; Taquet et al., 2021c; Williamson et al., 2020): age, 103 sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic 104 lower respiratory diseases, nicotine dependence, substance misuse, ischaemic heart disease 105 and other forms of heart disease, socioeconomic deprivation, cancer (and haematological 106 cancer in particular), chronic liver disease, stroke, dementia, organ transplant, rheumatoid arthritis, lupus, psoriasis, and disorders involving an immune mechanism. To capture these 107 108 risk factors in patients' health records, 55 variables were used. More details including ICD-10 109 codes are provided in the Appendix pp. 4-5. Cohorts were matched for all these variables, as 110 described below. In addition, cohorts were stratified by the date of the SARS-CoV-2 111 infection in 2-monthly periods (January 1 to February 28, 2021, March 1 to April 30, 2021, 112 May 1 to June 30, 2021, and July 1 to August 31, 2021) and matching was achieved independently within each period (guaranteeing that as many patients in the matched cohorts 113 114 had their SARS-CoV-2 infection in every 2-month period). 115

116 **Outcomes**

We investigated the 6-month incidence of all acute and post-acute outcomes which have been shown to be significantly associated with COVID-19 in four large-scale studies based on

119	electronic health records	(Al-Aly et al., 2021; Daugherty et al., 2021; Taquet et al., 20	021b,
-----	---------------------------	---	-------

- 120 2021a), namely:
- 121 Hospitalisation
- 122 Intensive Care Unit (ICU) admission
- 123 Death
- 124 Intubation/Ventilation
- 125 Respiratory failure
- 126 Hypoxaemia
- 127 Oxygen requirement
- Long COVID feature (any and each of the following as defined in Ref. 18)
- 129 Abdominal symptoms
- 130 Abnormal breathing
- 131 Anxiety/Depression
- 132 Chest/Throat pain
- 133 Cognitive symptoms
- 134 Fatigue
- 135 Headache
- 136 Myalgia
- 137 Other pain
- 138 Hypertension
- 139 Arrhythmia
- 140 Cardiac failure
- 141 Cardiomyopathy
- 142 Myocarditis
- 143 Coronary disease

8

144	•	Hypercoagulopathy/Deep vein thrombosis (DVT)/Pulmonary embolism (PE)
145	•	Ischaemic stroke
146	•	Cerebral haemorrhage
147	•	Peripheral neuropathy
148	•	Seizures
149	•	Type 2 diabetes mellitus
150	•	Liver disease
151	•	Kidney disease
152	•	Interstitial lung disease
153	•	Urticaria
154	•	Sleep disorders
155	•	Gastro-oesophageal reflux disease (GORD)
156	•	Hair loss
157	•	Hyperlipidaemia
158	•	Joint pain
159	•	Obesity
160	•	Anosmia
161	•	Nerve/nerve root/plexus disorder
162	•	Myoneural junction/muscle disease
163	•	Psychotic disorder
164	•	Mood disorder
165	•	Anxiety disorder
166		
167	Each	outcome was defined as the set of corresponding ICD-10, CPT, and VA Formulary

codes as specified in the original study which showed their association with COVID-19. To 168

169	account for death as a competing risk and thus address survivorship bias, each outcome was
170	analysed as part of a composite outcome with death as the other component (Manja et al.,
171	2017). While necessary to address survivorship bias, this approach is unlikely to provide
172	insight into the risk of outcomes which are much rarer than death itself. The analysis was
173	performed on October 12, 2021. More details, and ICD-10/CPT/VA Formulary codes, are
174	provided in the Appendix pp. 5-6.
175	
176	Secondary analyses
177	We assessed whether the associations between prior vaccinations and outcomes of SARS-
178	CoV-2 infection were moderated by the number of vaccine doses received and by age at the
179	time of infection. This was achieved by restricting the primary cohort to (i) those who had
180	received only one vaccine dose at least 14 days before infection, (ii) those who had received
181	two vaccine doses 14 days before infection, (iii) those <60 years-old, and (iv) those ≥ 60
182	years-old. For the latter two subgroup analyses, the control cohorts were also restricted to
183	those ≤ 60 and ≥ 60 years-old respectively.
184	
185	Statistical analyses
186	Propensity score matching (carried out within the TriNetX network) was used to create
187	cohorts with matched baseline characteristics (Austin, 2011). Propensity score 1:1 matching
188	used a greedy nearest neighbour approach with a caliper distance of 0.1 pooled standard
189	deviations of the logit of the propensity score. Any characteristic with a standardized mean
190	difference (SMD) between cohorts lower than 0.1 is considered well matched (Haukoos and
191	Lewis, 2015). The Kaplan-Meier estimator was used to estimate the incidence of each
192	outcome. Hazard ratios (HRs) with 95% confidence intervals were calculated using the Cox
193	model and the null hypothesis of no difference between cohorts was tested using log-rank

194	tests. The proportional hazard assumption was tested using the generalized Schoenfeld
195	approach. When the assumption was violated, a time-varying HR was estimated using natural
196	cubic splines fitted to the log-cumulative hazard (Royston and Parmar, 2002). The
197	contribution of the individual outcomes of interest within the composite endpoint (with death
198	as the other component) was reported as the number of events of interest over the total
199	number of events (e.g. the number of respiratory failures over the number of respiratory
200	failures or deaths).
201	
202	We statistically tested whether the associations between prior COVID-19 vaccine and
203	outcomes of SARS-CoV-2 infection was moderated by age. This was achieved for each
204	outcome by testing whether the ratio between the HR in those ≥ 60 and the HR in those < 60
205	years-old was statistically significantly different from 1. Similarly, moderation by the number
206	of vaccine doses was achieved by testing whether the ratio between the HR in those who had
207	received 1 dose and the HR in those who had received 2 doses at the time of infection was
208	statistically significantly different from 1.
209	
210	Further details are provided in the appendix p. 7. Statistical analyses were conducted in R
211	version 3.6.3 except for the log-rank tests which were performed within TriNetX. Statistical
212	significance was set at two-sided p-values <0.05. Bonferroni correction for multiple
213	comparisons was applied to correct for the simultaneous assessments of 45 outcomes in the
214	primary analysis. A REporting of studies Conducted using Observational Routinely-collected
215	health Data (RECORD) statement was completed (see Appendix).

11

216 **Results**

217 A total of 10,024 individuals with SARS-CoV-2 infections recorded at least 2 weeks after a 218 first dose of vaccine against COVID-19 were identified (mean [SD] age at infection: 57.0 219 [17.9] years-old, 59.4% female). Among them, 65.1% were vaccinated with BNT162b2 220 'Pfizer/BioNTech', 9.0% with mRNA-1273 'Moderna', 1.6% with Ad26.COV2.S 'Janssen', 221 and 24.4% with unspecified subtype. 9479 of these individuals were matched to 9479 222 individuals with SARS-CoV-2 infections who did not have a COVID-19 vaccine before 223 SARS-CoV-2 infection. The main demographic features and comorbidities of both cohorts 224 are summarised in table 1 (additional baseline characteristics presented in the appendix pp. 18-19). Adequate propensity-score matching (standardised mean difference < 0.1) was 225 226 achieved for all comparisons and baseline characteristics and all subgroups (appendix pp. 18-227 27).

228

229 We estimated the HRs for the occurrence within 6 months of infection of a range of health 230 events (combined with death in composite endpoints) previously documented to occur at an 231 increased rate after SARS-CoV-2 infections. As seen in Fig. 1 and Fig. 2 (see Appendix pp. 232 9-12 for all Kaplan-Meier curves and pp. 28-29 for a summary table), compared to 233 unvaccinated individuals, those who were vaccinated at the time of SARS-CoV-2 infection 234 were at a significantly lower risk of composite outcome of death and respiratory failure (HR 235 0.70, 95% CI 0.63-0.78, Bonferroni-corrected p<0.0001), intubation/ventilation (HR 0.72, 236 95% CI 0.61-0.84, Bonferroni-corrected p=0.0024), hypoxaemia (HR 0.72, 95% CI 0.65-237 0.80, Bonferroni-corrected p<0.0001), seizures (HR 0.73, 95% CI 0.62-0.86, Bonferroni-238 corrected p=0.0057), ICU admission (HR 0.75, 95% CI 0.65-0.85, Bonferroni-corrected 239 p<0.0001), psychotic disorder (HR 0.75, 95% CI 0.63-0.89, Bonferroni-corrected p=0.036), 240 hair loss (HR 0.75, 95% CI 0.64-0.88, Bonferroni-corrected p=0.024), hypercoagulopathy or

12

241 venous thromboembolism (HR 0.81, 95% CI 0.72-0.91, Bonferroni-corrected p=0.014), and 242 oxygen requirement (HR 0.83, 95% CI 0.75-0.92, Bonferroni-corrected p=0.011). In contrast, 243 there was no significant difference in the risk of many other outcomes including composite of 244 death and any long-COVID feature (HR 1.01, 95% CI 0.96-1.05, p=0.83, Bonferroni-245 corrected p=1.0), Type 2 diabetes mellitus (HR 0.97, 95% CI 0.90-1.05, p=0.45, Bonferronicorrected p=1.0), mood disorder (HR 1.05, 95% CI 0.96-1.15, p=0.27, Bonferroni-corrected 246 247 p=1.0), and anxiety disorder (HR 1.06, 95% CI 0.97-1.15, p=0.20, Bonferroni-corrected 248 p=1.0), among others. There was no violation of the proportionality assumption for 35 out of 249 45 outcomes (Appendix pp. 30-31 and p. 13 for the time-varying HR for the other 10 250 outcomes). For most of the other 10 outcomes (including death), the time-varying HRs were 251 significantly lower than 1 (indicating a stronger association with vaccination status) earlier in 252 the follow-up window.

253

254 Besides the outcomes shown to be significantly associated with vaccination in the primary 255 analysis, those who had received two vaccine doses at the time of SARS-CoV-2 infection 256 were also at a significantly lower risk of myalgia, myocarditis, cerebral haemorrhage, 257 interstitial lung disease, urticaria, anosmia, and myoneural junction/muscle disease (each as 258 composite endpoints with death), and at a significantly lower risk of death (Fig. 3 and 259 appendix pp. 14, 32-33). In those who had received only one vaccine dose, HRs followed a 260 similar pattern, though they were generally closer to 1 (Fig. 3 and appendix pp. 15, 34-35). 261 For each of the outcome, the HR in those who had received 2 doses was not statistically 262 significantly different from the HR in those who had received 1 vaccine dose (appendix pp. 263 36-37).

265	We found a substantial effect of age on the results. Many HRs in younger individuals (< 60
266	years-old) were in general lower (i.e. favouring vaccination even more) for outcomes
267	significantly associated with vaccination (Fig. 3 and appendix pp. 16, 38-39). These lower
268	HRs were observed against the backdrop of lower absolute risks for most outcomes among
269	younger individuals (appendix pp. 38-39). In contrast, in individuals ≥60 years-old, although
270	most trends were similar to those in the younger group, none of the HRs were statistically
271	significantly different from 1 after Bonferroni correction (Fig. 3 and appendix pp. 17, 40-41).

medRxiv preprint doi: https://doi.org/10.1101/2021.10.26.21265508; this version posted November 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .



272

Fig. 1 – Hazard ratios for the outcome within 6 months of infection with SARS-CoV-2 between individuals
 vaccinated vs. unvaccinated against COVID-19. HR lower than 1 indicate outcomes less common among
 vaccinated individuals. Horizontal bars represent 95% confidence intervals. Each outcome is a composite
 endpoint with death as a component to address competing risks. The contribution of the outcome of interest to
 the overall incidence of the composite endpoint is encoded by the colour.



279

280 Fig. 2 - Kaplan-Meier estimates for the incidence of outcomes of SARS-CoV-2 infection between vaccinated 280 281 282 283 and unvaccinated individuals in the whole cohort (top) and for the incidence of death in different subgroups (bottom). 95% confidence intervals are shaded. For Kaplan-Meier curves of all other outcomes in the whole cohort, see appendix pp. 9-12. DVT=Deep vein thrombosis. PE=Pulmonary embolism.



285

286 Fig. 3 - Hazard ratios for the outcomes within 6 months of infection with SARS-CoV-2 between individuals 287 who received one dose of the vaccine (vs. unvaccinated individuals), those who received two doses of the 288 vaccine (vs. unvaccinated individuals), vaccinated vs. unvaccinated individuals under the age of 60, and 289 vaccinated vs. unvaccinated individuals over the age of 60. HR lower than 1 indicate outcomes less common 290 among vaccinated individuals. Horizontal bars represent 95% confidence intervals. Each outcome is a 291 composite endpoint with death as a component to address competing risks. The contribution of the outcome of 292 interest to the overall incidence of the composite endpoint is encoded by the colour. Only a subset of 293 representative outcomes is displayed. The same figures with all outcomes are presented in the appendix pp. 14-294 17.

For all but one outcomes associated with vaccination status in the	primary a	inalysis,	the HR in
--	-----------	-----------	-----------

- 297 the older group was significantly higher (i.e. favouring vaccination less) than the HR in the
- 298 younger group (Appendix pp. 42-43). For instance, the HR for the composite outcome of
- 299 death or respiratory failure was 0.48 (95% CI 0.39-0.60) in individuals <60 years-old and
- 300 0.85 (95% CI 0.76-0.96) in those ≥60 years-old (ratio between the two: 1.77, 95% CI 1.38-
- 301 2.26, p<0.0001). The only exception was the composite of death and
- 302 hypercoagulopathy/DVT/PE (HR in the older group 0.93, HR in the younger group 0.72,
- 303 ratio between the two 1.30, 95% CI 1.00-1.70, p=0.054).

17

304 Discussion

305 It is established that vaccination protects against hospitalisation, ICU admission, and death 306 from COVID-19 (Agrawal et al., 2021; Antonelli et al., 2021; Bahl et al., 2021; Butt et al., 307 2021; Cabezas et al., 2021; Glatman-Freedman et al., 2021; Haas et al., 2021; Hyams et al., 308 2021; Mateo-Urdiales et al., 2021; Roest et al., 2021) but little was known about other 309 outcomes of breakthrough SARS-CoV-2 infections. The data presented in this study, from a 310 large-scale electronic health records network, confirm that vaccination protects against death 311 and ICU admission following breakthrough SARS-CoV-2 infection and provide estimates of 312 HR for these outcomes in a general population. Our study also shows that vaccination against 313 COVID-19 is associated with lower risk of additional outcomes that had not been assessed in 314 previous studies, namely respiratory failure, hypoxaemia, oxygen requirement, 315 hypercoagulopathy or venous thromboembolism, seizures, psychotic disorder, and hair loss. 316 317 On the other hand, previous vaccination does not appear to be protective against several 318 previously documented outcomes of COVID-19 such as long-COVID features, arrhythmia, 319 joint pain, type 2 diabetes, liver disease, sleep disorders, and mood and anxiety disorders. The 320 narrow confidence intervals (related to the high incidence of these outcomes post-COVID) 321 rules out the possibility that these negative findings are merely a result of lack of statistical

322 power. The inclusion of death in a composite endpoint with these outcomes rules out 323 survivorship bias as an explanation. Instead, these negative findings might indicate that these 324 outcomes arise through different pathophysiological mechanisms than outcomes which are 325 affected by prior vaccination. For example, for anxiety and depression, it might be that 326 antagonistic forces are at play with the protective effect of the vaccine being counteracted by 327 the additional stressor of being infected despite being vaccinated.

18

329 The absence of a protective effect against long-COVID features is concerning given the high 330 incidence and burden of these sequelae of COVID-19 (Taquet et al., 2021a). However, the risk of several individual long-COVID features were significantly associated with prior 331 332 vaccination (but did not survive correction for multiple comparisons): myalgia (HR 0.78, 95% CI 0.67-0.91), fatigue (HR 0.89, 95% CI 0.81-0.97), and pain (HR 0.90, 95% CI 0.81-333 334 0.99), with potentially additional protection after a second dose of the vaccine against 335 abnormal breathing (HR 0.89, 95% CI 0.81-0.98) and cognitive symptoms (HR 0.87, 95% CI 336 0.76-0.99). Relative differences in the incidence of individual long-COVID features might 337 explain why our findings differ from those of an app-based survey suggesting that 338 vaccination is overall protective against long-COVID symptoms (Antonelli et al., 2021). 339 Other reasons might also explain this difference. First, the present study used data routinely 340 collected from a general population rather than self-selected individuals. Second, this study 341 uses a large sample size and matches cohorts on a broad range of recorded comorbidities. To 342 further decrease selection bias, the control cohort of this study was selected among those 343 having received an influenza vaccine thus helping control for the confounding effect of 344 vaccine hesitancy and related health behaviours (Latkin et al., 2021). Third, by using 345 symptoms and diagnoses extracted from health records rather than self-reported, our study 346 might capture the most severe presentation of symptoms and these might be less prone to 347 demand characteristics and other forms of detection bias. Finally, there might be differences 348 in the type of vaccines used between the two study. In particular, no ChAdOx1 nCov-19 349 ('Oxford/AstraZeneca') vaccine was used in our study (as this vaccine is not used in the 350 USA). 351

The findings that vaccination against SARS-CoV-2 does not protect against some of the postacute outcomes of COVID-19 should not obscure the fact that vaccination remains an

19

354 important protective factor against these outcomes at the population level, since the best way 355 to prevent those outcomes is to prevent SARS-CoV-2 infection in the first place. This is also 356 the case in those ≥ 60 years-old (Polack et al., 2020). However, our results highlight that 357 some post-acute outcomes of SARS-CoV-2 (and notably long-COVID presentations) are likely to persist even after successful vaccination of the population, so long as breakthrough 358 359 infections occur. These findings thus help in determining the necessary service provision. 360 They also underline the urgency to identify other preventive or curative interventions to 361 mitigate the impact of such COVID-19 sequelae.

362

363 Death was included in a composite endpoint with each outcome of interest to address 364 competing risks (Manja et al., 2017). This implies that for outcomes much rarer than death 365 (which is the minority of outcomes investigated), HRs might be driven by death rather than 366 the outcome of interest. For instance, the 6-month incidence of psychotic disorders in the 367 unvaccinated cohort was 1.11% whereas the death rate was 4.5% in this cohort. Hence the 368 HR of 0.75 for the composite endpoint of death and psychotic disorder is in part driven by 369 differences in death rate. Observing the HR for the outcome of interest in isolation (i.e. not 370 composed with death) is informative so long as it is lower than 1. A HR lower than 1 371 suggests a lower rate of the outcome of interest despite survivorship bias (which in the 372 present study increases HRs). If the HR is higher than 1, it is impossible to know whether the 373 outcome is more common among vaccinated individuals or if it is a result of survivorship 374 bias. HRs for all outcomes in isolation are provided in Appendix pp. 44-53 for the primary 375 and secondary analyses. For instance, the HR for psychotic disorder measured in isolation 376 was 0.79, indicating that the incidence of this outcome might indeed be lower in vaccinated 377 than unvaccinated individuals and its significant HR might not be merely driven by differences in death rates. 378

20

379

380 Importantly, the protective effects of the vaccine against acute severity of infection and some 381 post-acute sequelae appears to affect primarily those <60 years-old. In this group, the effects 382 were large and robust, whereas in the ≥ 60 year-old group, effects were smaller and not 383 statistically robust. This finding regarding age cannot be explained by differences in 384 statistical power since the younger and older subgroups have similar sample sizes (4633 and 385 4657 respectively) and outcomes are in general more frequent in the older subgroup. Instead, 386 it might be due to differences in contributions of pathophysiological pathways of 387 breakthrough infections between younger and older individuals. In younger patients, effective 388 B-cell response to vaccination might be followed by infection with variants against which 389 antibodies have less neutralising activity (Wu et al., 2021). In older patients, the B-cell 390 response to vaccination might itself be ineffective (Siegrist and Aspinall, 2009) so that the 391 clinical presentation of breakthrough infection is similar to that of infection in unvaccinated 392 individuals. Regardless of explanation, the seemingly age-limited benefits of vaccination on 393 the severity and sequelae of SARS-CoV-2 infection has clear public health implications. 394 395 This study has several limitations beyond those inherent to research using EHRs (Casey et 396 al., 2016; Taquet et al., 2021b) (summarised in the appendix p. 2) such as the unknown 397 completeness of records, no validation of diagnoses, and sparse information on 398 socioeconomic and lifestyle factors. First, we do not know which SARS-CoV-2 variant 399 individual patients were infected with and this might affect the protective effect of vaccines. 400 There is evidence that variants of concerns are overrepresented in breakthrough infections 401 (McEwen et al., 2021). Since such variants tend to be associated with worse outcomes 402 (Nyberg et al., 2021), their enrichment in breakthrough infections means that some HRs 403 presented in this study might be conservative estimates. Second, it might be that vaccination

21

404 status affects the probability to seek or receive medical attention, particularly for less severe 405 outcomes. Third, this study says nothing about the outcomes in patients infected with SARS-406 CoV-2 but who did not get tested nor diagnosed with COVID-19. Fourth, this study did not 407 investigate whether the association between vaccination status and outcomes of SARS-CoV-408 2 infection was moderated by timing of the vaccine with respect to the infection. Fifth, we 409 could not compare the different vaccines against each other since the majority had received 410 the Pfizer/BioNTech vaccine. Finally, as an observational study, causation cannot be inferred 411 (though the specificity of the association with some outcomes and not others and the dose-412 response relationship support causality as an explanation). 413 414 In summary, the present data show that prior vaccination against COVID-19, especially after 415 two doses, is associated with significantly less risk of many but not all outcomes of COVID-416 19, in younger but not older individuals. These findings may inform service planning, 417 contribute to forecasting public health impacts of vaccination programmes, and highlight the 418 urgent need to identify or develop additional preventive and curative interventions for 419 sequelae of COVID-19.

420 Role of Funding Source

The funding source had no role in study design; in the collection, analysis, and interpretationof data; in the writing of the report; and in the decision to submit the paper for publication.

423 Contributors

424 MT and PJH conceptualised the study, acquired funding, defined the methodology, and were 425 involved in project administration and supervision. MT and QD curated the data, did the 426 formal analyses, and validated the findings. MT created visualizations and wrote the original

22

427 draft. MT, QD, and PJH reviewed and edited the manuscript for style and content. PJH and 428 MT were granted unrestricted access to the TriNetX Analytics network for the purposes of 429 research, and with no constraints on the analyses performed nor the decision to publish. The 430 corresponding author had full access to all the data in the study, conducted the analysis, and 431 takes responsibility for the integrity of the data and the accuracy of the data analysis.

432 Acknowledgments

- 433 Work supported by the National Institute for Health Research (NIHR) Oxford Health
- 434 Biomedical Research Centre (grant BRC-1215-20005). MT is an NIHR Academic Clinical
- 435 Fellow and NIHR Oxford Health BRC Senior Research Fellow. QD is supported by the
- 436 Medical Research Council (SUAG/077 G101400) and an AXA Research Fund Fellowship
- 437 (G102329). The views expressed are those of the authors and not necessarily those of the UK
- 438 National Health Service, NIHR, or the UK Department of Health.

439 **Declarations of interest**

440 The authors declare no conflict of interest.

441 Data sharing

- 442 The TriNetX system returned the results of these analyses as csv files which were
- 443 downloaded and archived. Data presented in this paper and the Appendix can be freely
- 444 accessed at [URL to be added on publication]. Additionally, TriNetX will grant access to
- 445 researchers if they have a specific concern (via the third-party agreement option).

References

- Agrawal, U., Katikireddi, S.V., McCowan, C., Mulholland, R.H., Azcoaga-Lorenzo, A., Amele, S., Fagbamigbe, A.F., Vasileiou, E., Grange, Z., Shi, T., Kerr, S., Moore, E., Murray, J.L.K., Shah, S.A., Ritchie, L., O'Reilly, D., Stock, S.J., Beggs, J., Chuter, A., Torabi, F., Akbari, A., Bedston, S., McMenamin, J., Wood, R., Tang, R.S.M., de Lusignan, S., Hobbs, F.D.R., Woolhouse, M., Simpson, C.R., Robertson, C., Sheikh, A., 2021. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(21)00380-5
- Al-Aly, Z., Xie, Y., Bowe, B., 2021. High-dimensional characterization of post-acute sequalae of COVID-19. Nature. https://doi.org/10.1038/s41586-021-03553-9
- Antonelli, M., Penfold, R.S., Merino, J., Sudre, C.H., Molteni, E., Berry, S., Canas, L.S., Graham, M.S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., Österdahl, M.F., Cheetham, N.J., Drew, D.A., Nguyen, L.H., Pujol, J.C., Hu, C., Selvachandran, S., Polidori, L., May, A., Wolf, J., Chan, A.T., Hammers, A., Duncan, E.L., Spector, T.D., Ourselin, S., Steves, C.J., 2021. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(21)00460-6
- Austin, P.C., 2011. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav. Res. 46, 399-424.
- Bahl, A., Johnson, S., Maine, G., Garcia, M.H., Nimmagadda, S., Qu, L., Chen, N.-W., 2021. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. Lancet Reg Health Am 100065.
- Butt, A.A., Nafady-Hego, H., Chemaitelly, H., Abou-Samra, A.-B., Khal, A.A., Coyle, P.V., Kanaani, Z.A., Kaleeckal, A.H., Latif, A.N., Masalmani, Y.A., Bertollini, R., Raddad, L.J.A., 2021. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. Int. J. Infect. Dis. 110, 353-358.
- Cabezas, C., Coma, E., Mora-Fernandez, N., Li, X., Martinez-Marcos, M., Fina, F., Fabregas, M., Hermosilla, E., Jover, A., Contel, J.C., Lejardi, Y., Enfedaque, B., Argimon, J.M., Medina-Peralta, M., Prieto-Alhambra, D., 2021. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. BMJ 374, n1868.
- Casey, J.A., Schwartz, B.S., Stewart, W.F., Adler, N.E., 2016. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu. Rev. Public Health 37, 61-81.

medRxiv preprint doi: https://doi.org/10.1101/2021.10.26.21265508; this version posted November 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

- Daugherty, S.E., Guo, Y., Heath, K., Dasmariñas, M.C., Jubilo, K.G., Samranvedhya, J., Lipsitch, M., Cohen, K., 2021. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 373, n1098.
- de Lusignan, S., Dorward, J., Correa, A., Jones, N., Akinyemi, O., Amirthalingam, G., Andrews, N., Byford, R., Dabrera, G., Elliot, A., Ellis, J., Ferreira, F., Lopez Bernal, J., Okusi, C., Ramsay, M., Sherlock, J., Smith, G., Williams, J., Howsam, G., Zambon, M., Joy, M., Hobbs, F.D.R., 2020. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30371-6
- Glatman-Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., Keinan-Boker, L., 2021. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. EBioMedicine 72, 103574.
- Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., Southern, J., Swerdlow, D.L., Jodar, L., Levy, Y., Alroy-Preis, S., 2021. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829.

Haukoos, J.S., Lewis, R.J., 2015. The propensity score. JAMA 314, 1637–1638.

- Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., Heath, R., Tuner, A., Friedrich, Z., Morrison, L., Ruffino, G., Antico, R., Adegbite, D., Szasz-Benczur, Z., Garcia Gonzalez, M., Oliver, J., Danon, L., Finn, A., 2021. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(21)00330-3
- Latkin, C.A., Dayton, L., Yi, G., Colon, B., Kong, X., 2021. Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US. PLoS One 16, e0246970.
- Manja, V., AlBashir, S., Guyatt, G., 2017. Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations. J. Clin. Epidemiol. 82, 4–11.
- Mateo-Urdiales, A., Spila Alegiani, S., Fabiani, M., Pezzotti, P., Filia, A., Massari, M., Riccardo, F., Tallon, M., Proietti, V., Del Manso, M., Puopolo, M., Spuri, M., Morciano, C., D'Ancona, F.P., Da Cas, R., Battilomo, S., Bella, A., Menniti-Ippolito, F., Italian Integrated Surveillance of COVID-19 study group, on behalf of the Italian COVID-19 vaccines registry, 2021. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. Euro Surveill. 26. https://doi.org/10.2807/1560-7917.ES.2021.26.25.2100507

- McEwen, A.E., Cohen, S., Bryson-Cahn, C., Liu, C., Pergam, S.A., Lynch, J., Schippers, A., Strand, K., Whimbey, E., Mani, N.S., Zelikoff, A.J., Makarewicz, V.A., Brown, E.R., Bakhash, S.A.M., Baker, N.R., Castor, J., Livingston, R.J., Huang, M.-L., Jerome, K.R., Greninger, A.L., Roychoudhury, P., 2021. Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab581
- Nixon, D.F., Ndhlovu, L.C., 2021. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med.
- Nyberg, T., Twohig, K.A., Harris, R.J., Seaman, S.R., Flannagan, J., Allen, H., Charlett, A., De Angelis, D., Dabrera, G., Presanis, A.M., 2021. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ 373, n1412.
- Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., Bailey, R., Swanson, K.A., Roychoudhury, S., Koury, K., Li, P., Kalina, W.V., Cooper, D., Frenck, R.W., Jr, Hammitt, L.L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D.B., Mather, S., Dormitzer, P.R., Şahin, U., Jansen, K.U., Gruber, W.C., C4591001 Clinical Trial Group, 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615.
- Roest, S., Hoek, R.A.S., Manintveld, O.C., 2021. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med.
- Royston, P., Parmar, M.K.B., 2002. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in Medicine. https://doi.org/10.1002/sim.1203
- Siegrist, C.-A., Aspinall, R., 2009. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185–194.
- Taquet, M., Dercon, Q., Luciano, S., Geddes, J.R., Husain, M., Harrison, P.J., 2021a. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773.
- Taquet, M., Geddes, J.R., Husain, M., Luciano, S., Harrison, P.J., 2021b. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8, 416-427.
- Taquet, M., Luciano, S., Geddes, J.R., Harrison, P.J., 2021c. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 8, 130–140.
- Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H.I., MacKenna, B., Tomlinson, L., Douglas, I.J., Rentsch, C.T., Mathur, R., Wong, A.Y.S., Grieve,

R., Harrison, D., Forbes, H., Schultze, A., Croker, R., Parry, J., Hester, F., Harper, S., Perera, R., Evans, S.J.W., Smeeth, L., Goldacre, B., 2020. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. https://doi.org/10.1038/s41586-020-2521-4

Wu, K., Werner, A.P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G.B.E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., Moliva, J.I., Sullivan, N.J., Graham, B.S., Carfi, A., Corbett, K.S., Seder, R.A., Edwards, D.K., 2021. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468-1470.

27

Table 1 - Baseline characteristics and major outcomes for the vaccinated and unvaccinated cohorts, before and after propensity score matching. Only characteristics with an overall prevalence above 5% after matching are presented here; for additional baseline characteristics see appendix pp. 18-19

	Vaccinated (unmatched)	Unvaccinated (unmatched)	Vaccinated (matched)	Unvaccinated (matched)
COHORT SIZE	10024	83957	9479	9479
DEMOGRAPHICS				
Age; mean (SD)	57.0 (17.9)	51.9 (23.1)	56.5 (18.0)	57.6 (20.6)
Sex; n (%) female	5950 (59.4)	48968 (58.3)	5676 (59.9)	5761 (60.8)
Race ; n (%)				
White	7208 (71.9)	57310 (68.3)	6783 (71.6)	6873 (72.5)
Black or African American	1584 (15.8)	16296 (19.4)	1540 (16.2)	1514 (16.0)
Unknown	802 (8.0)	7843 (9.3)	783 (8.3)	756 (8.0)
Ethnicity; n (%)				
Hispanic or Latino	1097 (10.9)	7539 (9.0)	1015 (10.7)	974 (10.3)
Not Hispanic of Latino	7199 (71.8)	63015 (75.1)	6780 (71.5)	6793 (71.7)
Unknown	1728 (17.2)	13403 (16.0)	1684 (17.8)	1712 (18.1)
		(2000)	()	(1011)
COMORBIDITIES				
BMI; mean (SD)	30.0 (7.4)	29.7 (8.3)	30.1 (7.4)	30.2 (7.5)
Overweight and obesity ; n (%)	3175 (31.7)	30363 (36.2)	3086 (32.6)	3263 (34.4)
Blood pressure; mean (SD)				
Diastolic	74.7 (11.5)	73.0 (12.1)	74.6 (11.5)	73.1 (11.6)
Systolic	127.6 (19.0)	124.2 (19.6)	127.5 (18.8)	126.0 (19.4)
Hypertensive diseases; n (%)	5227 (52.1)	46211 (55.0)	5060 (53.4)	5197 (54.8)
Diabetes mellitus; n (%)				
Type 2 diabetes mellitus	2508 (25.0)	24073 (28.7)	2426 (25.6)	2551 (26.9)
Chronic lower respiratory diseases; n (%)				
Asthma	1526 (15.2)	17665 (21.0)	1502 (15.8)	1491 (15.7)
Bronchitis, not specified as acute or chronic	887 (8.8)	10121 (12.1)	870 (9.2)	867 (9.1)
Other chronic obstructive pulmonary disease	884 (8.8)	10493 (12.5)	871 (9.2)	958 (10.1)
Nicotine dependence; n (%)	929 (9.3)	11509 (13.7)	917 (9.7)	935 (9.9)
Psychiatric comorbidities; n (%)				
Anxiety disorders	3187 (31.8)	31966 (38.1)	3098 (32.7)	3159 (33.3)
Substance misuse	1351 (13.5)	16299 (19.4)	1334 (14.1)	1373 (14.5)
Mood disorders	2453 (24.5)	27245 (32.5)	2408 (25.4)	2458 (25.9)
Heart disease; n (%)				
Ischemic heart diseases	2074 (20.7)	18880 (22.5)	2013 (21.2)	2114 (22.3)
Other forms of heart disease	3573 (35.6)	34359 (40.9)	3485 (36.8)	3607 (38.1)
Chronic kidney diseases; n (%)	1501 (15 0)	15125 (10.0)		
Chronic kidney disease (CKD)	1501 (15.0)	15137 (18.0)	14/1 (15.5)	1561 (16.5)
Hypertensive chronic kidney disease	783 (7.8)	8795 (10.5)	/61 (8.0)	812 (8.6)
Chronic liver diseases; n (%)	777 (7 3)	6530 (7.8)	705 (7 4)	730 (7 7)
Cerebral infarction; n (%)	497 (5.0)	5384 (6.4)	487 (5.1)	508 (5.4)
Neoplasms (any); n (%)	4184 (41.7)	34046 (40.6)	4038 (42.6)	4208 (44.4)
Disorders involving the immune mechanism; n (%)	810 (8.1)	5844 (7.0)	778 (8.2)	771 (8.1)